TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04273672

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Battery
Description: Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Battery
Description: Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).

Intervention type: BEHAVIORAL
Intervention: Voice, Speech and Language Analysis
Description: Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.

Intervention type: BEHAVIORAL
Intervention: Voice, Speech and Language Analysis
Description: Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.

Intervention type: BEHAVIORAL
Intervention: Questionnaires and Clinical Assessments
Description: Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.

Intervention type: BEHAVIORAL
Intervention: Questionnaires and Clinical Assessments
Description: Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.

Intervention type: GENETIC
Intervention: DNA Analysis
Description: Participants will have their blood drawn for DNA analysis.
Study: NCT01669720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
Study: NCT02801591

Intervention type: PROCEDURE
Intervention: Conventional ovarian stimulation proctol without rhGH
Study: NCT04614974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech Language Therapy
Description: Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech Language Therapy
Description: Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
Study: NCT02071381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW330SR 45mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW330SR 45mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1030 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1030 75mg
Study: NCT03618459

Intervention type: OTHER
Intervention: Phone questionnaire
Description: Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
Study: NCT00994032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous injection of cement into the vertebral body
Description: percutaneous injection of cement into the vertebral body

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: standard antalgic medical treatment
Study: NCT01774006

Intervention type: OTHER
Intervention: individual embryo culture or group culture
Description: Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish

Intervention type: OTHER
Intervention: individual embryo culture or group culture
Description: Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
Study: NCT02580890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
Study: NCT00543790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA-027
Description: PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
Study: NCT04351191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Regular dose
Description: Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Loading Dose
Description: Hydroxychloroquine administered as a loading dose only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care plus placebo
Study: NCT03899337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100mg capsule, PO, BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100mg capsule, PO, BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100mg capsule, PO, BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m\^2, IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m\^2, IV bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m\^2, IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m\^2, IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/m\^2, IV bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m\^2, IV bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m\^2, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m\^2, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m\^2, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40mg/m\^2, PO, OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40mg/m\^2, PO, OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 40mg/m\^2, PO, OD
Study: NCT02370602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^11C]T-773
Description: \[\^11C\]T-773 IV solution
Study: NCT01718769

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire STAMP
Description: Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire STAMP
Description: Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
Study: NCT03899337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m\^2, IV infusion
Study: NCT00417937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: 15% gel, topically applied once daily for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: 15% gel, topically applied twice daily for six weeks
Study: NCT01925079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Education
Description: Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up.
Study: NCT01015742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell Transplantation
Description: Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant.
Study: NCT02345057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05224791

Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
Study: NCT02607761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Video-Audio Media

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Video-Audio Media
Study: NCT05224791

Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy
Description: The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy
Description: The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption
Study: NCT00005776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled Nitric oxide at a concentration of 20 ppm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100% Oxygen
Study: NCT01951430

Intervention type: DRUG
Intervention: Antibiotic and antifungal drugs
Study: NCT02123693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Study: NCT03607448

Intervention type: DEVICE
Intervention: Freestyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
Study: NCT02302729

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrients
Description: Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrients
Description: Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive feeding
Description: Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Responsive feeding
Description: Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Riboflavin Vitamin B2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Riboflavin Vitamin B2
Study: NCT01895166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
Study: NCT01850680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT03282071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joyful Parenting Intervention
Description: * Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing).
Study: NCT02061189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise in a swimming pool during 6 months
Description: 10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
Study: NCT03386799

Intervention type: DEVICE
Intervention: E-motion device
Description: Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
Study: NCT01121497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
Study: NCT01850680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT05150730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi professional care
Description: Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
Study: NCT03879720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscope assisted endotracheal intubation [EAEI]
Description: Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscope assisted endotracheal intubation [EAEI]
Description: Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
Study: NCT03755505

Intervention type: DIAGNOSTIC_TEST
Intervention: obtain samples from sputum, feces and urine
Description: Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: obtain samples from sputum, feces and urine
Description: Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.